The Lustgarten Foundation and Break Through Cancer Announce New Clinical Trial Evaluating KRAS-targeted Immunotherapy Strategy for Pancreatic Cancer Newly recruiting Phase 1 study will evaluate a next-generation KRAS-targeted immunotherapy, revealing how pancreatic tumor microenvironment shapes treatment response News Release For Immediate Release Media Contact: Alexas Santiago asantiago@lustgarten.org UNIONDALE, New York, — The Lustgarten Foundation and Break Through Cancer today announced the launch of a new Phase 1 clinical trial evaluating a next-generation KRAS-targeted lymph-node stimulating immunotherapy strategy for pancreatic cancer. The study is now recruiting patients with pancreatic ductal adenocarcinoma (PDAC), representing a significant milestone for the organizations' Demystifying Pancreatic......

Continue reading

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells A multi-site trial pairs targeted therapy with next-generation MRD testing to track residual disease and uncover vulnerabilities in leukemia cells News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) December 11, 2025 – Acute myeloid leukemia (AML) is an aggressive blood cancer, with overall survival remaining approximately 30% at five years despite advances in therapy. Even when patients achieve remission, the disease often returns, fueled by a small number of leukemia cells that survive initial treatment, known as measurable residual disease (MRD). These remaining......

Continue reading

Real-Time Biopsies Uncover Hidden Response to Glioblastoma Therapy Early clinical trial results show that serial brain biopsies reveal immune activity in brain cancer not captured by standard scans News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) October 08, 2025 – A new study led by Break Through Cancer’s Accelerating Glioblastoma (GBM) Therapies Through Serial Biopsies TeamLab has revealed that an engineered virus therapy, CAN-3110, triggered powerful immune responses deep inside glioblastoma tumors that were invisible to standard imaging like MRI, according to early analyses of two patients with recurrent GBM. Published today in Science Translational Medicine,......

Continue reading

New Blood-Based Technology Tracks Tumor Evolution in Ovarian Cancer Patients Break Through Cancer researchers uncover hidden cell populations driving relapse — findings could pave the way for more targeted treatments News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) October 01, 2025 – A new study published in Nature uncovers how ovarian cancers evolve during treatment, and how blood samples taken throughout disease progression could help guide therapies more effectively. The research shows that drug-resistant cancer cell populations may exist long before treatment begins, and that tracking these populations over time can reveal vulnerabilities that may be......

Continue reading

New Study Finds Hidden Disease in Nearly Half of Ovarian Cancer Patients in ‘Remission’ Using minimally invasive surgery and blood tests Break Through Cancer TeamLab found cancer cells, new drug targets, and biological clues for future therapies News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) August 01, 2025 – Survival rates for advanced ovarian cancer have remained stagnant for over four decades, largely because it so often recurs. While patients respond well to initial surgery and chemotherapy, it comes back in 4 out of 5 cases. A new Break Through Cancer study published in Clinical Cancer......

Continue reading

Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current ‘Wait and See’ Approach Scientists are exploring if early intervention can prevent AML in high-risk patients, shifting the focus from monitoring to proactive prevention News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) July 10, 2025 – Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to evaluate the feasibility of early intervention for Clonal Hematopoiesis (CH), a precursor to acute myeloid leukemia (AML). This multi-institutional study focuses on high-risk patients, exploring a new approach to managing this pre-malignant......

Continue reading